Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv

trialsTrialRecruiting

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv

A phase 1/2 trial of Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Onconic Therapeutics Inc., now recruiting.

Overview Connected4

Overview

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05257993 by Onconic Therapeutics Inc., with 71 participants planned, started 2022-03-30 and due to reach its primary completion in 2030-04. Interventions recorded: JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

Setting

An Open-label, Dose-finding, Phase Ib/II Study to Assess the Safety, Tolerability of JPI-547, a Dual Inhibitor of PARP/Tankyrase, in Combination With Modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Phase

Phase 1/2

Sponsor

Onconic Therapeutics Inc.

Registry

Started

2022-03-30

Enrolled

71 enrolled

Connected

Similar pages

Trial
Saltikva for Metastatic Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Trial
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
PRIMUS 001
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Trial
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.

cancers

Metastatic pancreatic ductal adenocarcinoma Pancreatic ductal adenocarcinoma

technologies

Cytotoxic chemotherapy

drugs

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

Evidence strength22/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
71 enrolled+9
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT05257993

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Pancreatic ductal adenocarcinoma
Metastatic pancreatic ductal adenocarcinoma

Technologies

Cytotoxic chemotherapy

Products

Gemcitabine + nab-paclitaxel

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05257993/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05257993.

WebMCP tools registered on this page: onco_search, onco_get_entity.